Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Link
http://link.springer.com/article/10.1007/s10637-017-0521-5/fulltext.html
Reference17 articles.
1. Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, Pessin MS, Lamy C, Mas JL, Caplan LR (1996) A reversible posterior leukoencephalopathy syndrome. N Engl J Med 334:494–500
2. Fugate JE, Rabinstein AA (2015) Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol 14:914–925
3. Marinella MA, Markert RJ (2009) Reversible posterior leukoencephalopathy syndrome associated with anticancer drugs. Intern Med J 39:826–834
4. Kim CAK, Prince-Hiller J, Chu QS, Tankel K, Hennig R, Sawyer MB, Spratlin JL (2014) Atypical reversible posterior leukoencephalopathy syndrome (RPLS) induced by cediranib in a patient with metastatic rectal cancer. Investig New Drugs 32:1036–1045
5. Schutz FA, Choueiri TK, Sternberg CN (2011) Pazopanib: clinical development of a potent anti-angiogenic drug. Crit Rev Oncol Hematol 77:163–171
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Challenges in the Management of Stage IV Clear Cell Sarcoma of Soft Tissue in Young Adults: Case Report and Review of the Literature;Case Reports in Oncology;2024-09-04
2. Recent advances in the use of tyrosine kinase inhibitors against thyroid cancer;Expert Opinion on Pharmacotherapy;2024-08-12
3. Neuro-ophthalmic complications of modern anti-cancer drugs;Graefe's Archive for Clinical and Experimental Ophthalmology;2024-02-12
4. Posterior Reversible Encephalopathy Syndrome after Pazopanib Therapy;Diseases;2023-05-23
5. Posterior reversible encephalopathy syndrome after anlotinib treatment for small cell lung cancer: A case report and literature review;Frontiers in Pharmacology;2023-02-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3